Alliancebernstein L.P. grew its holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 27.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,600 shares of the biotechnology company’s stock after acquiring an additional 9,000 shares during the period. Alliancebernstein L.P. owned 0.10% of Seres Therapeutics worth $470,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of MCRB. Parametric Portfolio Associates LLC grew its position in Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock worth $240,000 after acquiring an additional 279 shares in the last quarter. American International Group Inc. grew its position in Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 727 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Seres Therapeutics by 14.4% during the 1st quarter. TIAA CREF Investment Management LLC now owns 110,076 shares of the biotechnology company’s stock worth $1,241,000 after buying an additional 13,825 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Seres Therapeutics by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after buying an additional 103,456 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Seres Therapeutics by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after buying an additional 9,060 shares during the period. 74.82% of the stock is owned by institutional investors.

MCRB has been the subject of several recent analyst reports. Seaport Global Securities reaffirmed a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Shares of Seres Therapeutics, Inc. (MCRB) opened at $9.97 on Monday. The company has a quick ratio of 6.86, a current ratio of 6.86 and a debt-to-equity ratio of 0.11. Seres Therapeutics, Inc. has a 1-year low of $8.85 and a 1-year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.00 million. During the same period last year, the company earned ($0.70) earnings per share. Seres Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. sell-side analysts forecast that Seres Therapeutics, Inc. will post -2.51 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Alliancebernstein L.P. Acquires 9,000 Shares of Seres Therapeutics, Inc. (MCRB)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/alliancebernstein-l-p-acquires-9000-shares-of-seres-therapeutics-inc-mcrb/1682034.html.

Seres Therapeutics Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics, Inc. (NASDAQ:MCRB).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.